Adar1 Capital analyst Mohit Gupta pitches new atopic dermatitis company
Mohit Gupta and Dan Schneeberger of Adar1 Capital discussed creating a new immunology firm in Austin, Texas, two years ago.
Analyst proposes building new biotech firm
Gupta walked into Schneeberger's office to suggest developing a company from the ground up. The proposed business would focus on creating long-acting antibody treatments for atopic dermatitis. Schneeberger usually invests in existing biotech companies rather than starting his own ventures.
Company aims to improve antibody therapy
The new entity intends to build a better treatment option specifically for patients with atopic dermatitis. This project represents a shift from Schneeberger's standard day job of investing in established drug developers. The idea was pitched within the context of Adar1 Capital's investment strategy.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.